ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ZNTL Zentalis Pharmaceuticals Inc

11.06
0.075 (0.68%)
After Hours
Last Updated: 16:07:53
Delayed by 15 minutes

Period:

Draw Mode:

Volume 474,113
Bid Price 10.09
Ask Price 11.16
News -
Day High 11.23

Low
9.56

52 Week Range

High
31.46

Day Low 10.77
Company Name Stock Ticker Symbol Market Type
Zentalis Pharmaceuticals Inc ZNTL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.075 0.68% 11.06 16:07:53
Open Price Low Price High Price Close Price Prev Close
11.10 10.77 11.23 11.06 10.985
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,770 474,113 $ 11.03 $ 5,229,710 - 9.56 - 31.46
Last Trade Time Type Quantity Stock Price Currency
16:20:00 2 $ 11.06 USD

Zentalis Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
784.82M 70.96M - 0 -292.19M -4.12 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Zentalis Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ZNTL Message Board. Create One! See More Posts on ZNTL Message Board See More Message Board Posts

Historical ZNTL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week12.4813.4610.3912.09751,873-1.42-11.38%
1 Month15.5816.26510.3913.63720,047-4.52-29.01%
3 Months11.4418.0710.3913.73846,557-0.38-3.32%
6 Months16.1518.249.5613.21957,618-5.09-31.52%
1 Year21.7431.469.5618.40885,212-10.68-49.13%
3 Years59.4087.199.5626.87618,525-48.34-81.38%
5 Years24.6987.199.5628.96522,295-13.63-55.20%

Zentalis Pharmaceuticals Description

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Your Recent History

Delayed Upgrade Clock